NEWS

Introducing the TargetEx Bulk Offer

Save today, secure tomorrow and grow together!

TargetEx Biosciences is pleased to announce the launch of the TargetEx Bulk Offer. The offer is available until July 31, 2026 and is tailored for organizations seeking both immediate savings and long-term value through a stable supplier relationship.

The TargetEx Bulk Offer is built around three complementary pillars: immediate cost savings through bulk purchasing, predictable fixed pricing until the end of 2027, and access to preferential R&D collaboration opportunities.

During the campaign period, partners benefit from a 20% discount on all bulk product orders, delivering immediate cost savings from the first purchase.

In addition to short-term savings, the offer provides long-term pricing stability. Partners who place their bulk orders by July 31, 2026, qualify for fixed, discounted pricing through the end of 2027, ensuring long-term price stability and predictable budgeting.

Beyond product supply, the TargetEx Bulk Offer also supports closer collaboration. Customers reaching a total annual purchase volume of EUR 50,000 become eligible for a 30% discount on their first R&D project, valid until the end of 2027, supporting long-term development and growth.

Our current product portfolio is available at www.targetex.com/products.
Contact us at info@targetex.com.

The TargetEx Bulk Offer remains available until July 31, 2026, providing an opportunity to reduce costs today, secure prices for tomorrow and build a strong, strategic partnership with our team.

More news mentions & press releases

New milestone in drug development

Promising compound has reached clinical phase with TargetEx contribution

Our reliability is guaranteed for the future

Once again we have successfully passed the renewal ISO audit.

RibonEx, the first off-the-shelf TargetEx product, is now available to everyone

We have launched our first finished product, the RNase inhibitor RibonEx.